Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
- PMID: 31427752
- DOI: 10.1038/s41380-019-0474-5
Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
Abstract
Predicting antidepressant treatment response has been a clinical challenge for major depressive disorder (MDD). The inflammation hypothesis of depression suggests that cytokines play a key role in the pathophysiology of MDD and alterations in peripheral cytokine levels are associated with antidepressant treatment outcome. Present meta-analysis aimed to examine the association between baseline peripheral cytokine levels and the response to antidepressant treatment and to evaluate whether changes of cytokine levels were associated with the response to antidepressant treatment in patients with MDD. Human-based studies published in any language in peer-reviewed journals were systematically searched from the PubMed, Embase and Web of Science databases, from inception up to October 2018. The search terms included cytokine, depressive disorder and antidepressant and their synonyms. Case-control or case-case studies reporting on levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, CRP, TNF-α, IFN-γ, GM-CSF, MIP-1α, and Eotaxin-1 in patients with MDD based on validated depression scales both before and after antidepressant treatment were included. Of 7408 identified records, 44 studies met inclusion. Standardized mean differences in each cytokine were evaluated, and random-effects meta-analyses were performed. MDD patients who responded to antidepressant treatment had lower baseline IL-8 levels than the nonresponders (Hedge's g = -0.28; 95%CI, -0.43 to -0.13; P = 0.0003; FDR = 0.004). Antidepressant treatment significantly decreased levels of TNF-α (Hedge's g = 0.60; 95%CI, 0.26-0.94; P = 0.0006; FDR = 0.004) only in responders, and responders showed significantly more decreased TNF-α levels compared with nonresponders (P = 0.046). These findings suggested that alterations in peripheral cytokine levels were associated with antidepressant treatment outcomes in MDD. Further investigations are warranted to elucidate sources of heterogeneity and examine the potentiality of using inflammatory cytokines as novel predictive markers for the pharmacological treatment of MDD.
Similar articles
-
Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis.Mol Neurobiol. 2018 May;55(5):4195-4206. doi: 10.1007/s12035-017-0632-1. Epub 2017 Jun 13. Mol Neurobiol. 2018. PMID: 28612257
-
Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):217-226. doi: 10.1016/j.pnpbp.2017.04.026. Epub 2017 Apr 23. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 28445690
-
Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder.Int Immunopharmacol. 2023 May;118:110108. doi: 10.1016/j.intimp.2023.110108. Epub 2023 Mar 31. Int Immunopharmacol. 2023. PMID: 37004349
-
Painful physical symptoms and antidepressant treatment outcome in depression: a systematic review and meta-analysis.Mol Psychiatry. 2024 Aug;29(8):2560-2567. doi: 10.1038/s41380-024-02496-7. Epub 2024 Mar 13. Mol Psychiatry. 2024. PMID: 38480874
-
Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis.Eur Neuropsychopharmacol. 2020 Dec;41:40-51. doi: 10.1016/j.euroneuro.2020.09.633. Epub 2020 Sep 24. Eur Neuropsychopharmacol. 2020. PMID: 32980240
Cited by
-
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study.Front Psychiatry. 2024 Jun 24;15:1415505. doi: 10.3389/fpsyt.2024.1415505. eCollection 2024. Front Psychiatry. 2024. PMID: 39045550 Free PMC article.
-
Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic review.Ann Gen Psychiatry. 2024 Aug 27;23(1):31. doi: 10.1186/s12991-024-00514-0. Ann Gen Psychiatry. 2024. PMID: 39192245 Free PMC article. Review.
-
Adult hippocampal neurogenesis: pharmacological mechanisms of antidepressant active ingredients in traditional Chinese medicine.Front Pharmacol. 2023 Dec 12;14:1307746. doi: 10.3389/fphar.2023.1307746. eCollection 2023. Front Pharmacol. 2023. PMID: 38152691 Free PMC article. Review.
-
Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression.Eur Arch Psychiatry Clin Neurosci. 2024 Jun;274(4):849-865. doi: 10.1007/s00406-023-01704-9. Epub 2023 Nov 18. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 37980294
-
Selected Biomarkers of Depression: What Are the Effects of Cytokines and Inflammation?Int J Mol Sci. 2022 Dec 29;24(1):578. doi: 10.3390/ijms24010578. Int J Mol Sci. 2022. PMID: 36614020 Free PMC article. Review.
References
-
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40. - DOI
-
- Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry. 1995;19:11–38. - DOI
-
- Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous